Skip to main content

Graham Pawelec

New Content Item (1)Graham Pawelec received an MA in Natural Sciences in 1978 and a PhD in Transplantation Immunology in 1982 from the University of Cambridge, UK, and the Dr. habil and Venia Legendi from the University of Tübingen, Germany, where he became Professor of Experimental Immunology in 1997. From 1999 to 2017 he led the Tübingen Ageing and Tumour Immunology (TATI) group within the Second Department of Internal Medicine, University of Tübingen Hospitals System. He remains affiliated part-time Faculty at the department of Immunology, University of Tübingen. He is currently affiliated with the Cancer Solutions Program, Health Sciences North Research Institute of Canada, Sudbury, ON, and is a Visiting Professor at Nottingham Trent University, UK, King´s College London, London, UK, and is an Honorary Professor at Manchester University, UK.

He is Co-Editor-in Chief of the Journal of Ageing and Longevity and is Deputy or Associate Editor of several other journals. He has authored or co-authored >300 peer-reviewed original articles from a total of over 500 PubMed-listed publications, has edited 3 books and co-edited several others (as of September 2021 in Google Scholar >32,500 citations, H-index 97). He has coordinated three European Union collaborative programs on Immunosenescence (EUCAMBIS, ImAginE and T-CIA) and two on cancer vaccine research (EUCAPS, ESTDAB). He was a member of several Advisory Boards on Immunosenescence and Vaccination, and consults for Repair Biotechnology, Inc. In 2015 he was elected a Fellow of the Gerontological Society of America, and is or was a member of several Scientific Advisory Boards (the WHO Initiative for Vaccine Research 2008, the Pfizer European Healthcare Landscape in the Context of Adult Vaccines 2016, Seqirus 2019, Repair Biotechnologies 2019), and several others relevant to immunity and ageing. In 2021 he was nominated as the leading worldwide Expert on Immunosenescence, see and is also recognized as an Expertscape World Expert in Aging, see

His research interests remain centered on immunogerontology, vaccination, and cancer immunology/immunotherapy.

Annual Journal Metrics

  • 2022 Citation Impact
    7.9 - 2-year Impact Factor
    6.9 - 5-year Impact Factor
    1.379 - SNIP (Source Normalized Impact per Paper)
    2.387 - SJR (SCImago Journal Rank)

    2023 Speed
    2 days submission to first editorial decision for all manuscripts (Median)
    102 days submission to accept (Median)

    2023 Usage 
    1,115 Altmetric mentions